Case Discussion: What JAK Inhibitor Should I Use in a Transfusion-Dependent Patient With MF With Platelets > 50 × 109/L?
MP3•Episode home
Manage episode 433877220 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
…
continue reading
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
585 episodes